Developer docs
API playgroundTry for free, no card

Search company profiles

Actinogen Medical

Full company profile

uuid0007uc4

Namestring
Actinogen Medical
Legal namestring
Actinogen Medical Limited
Company typeenum
Public
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSydney, Australia
HQ citystring
Sydney
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biotechnology, neurological therapeutics, Alzheimer's disease treatment, CNS drug development, cortisol inhibition therapy
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Neurology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-revenue clinical stage company. Xanamem is an investigational product not yet approved for commercial use. The company is preparing for potential future commercialization pending successful clinical trial outcomes.

actinogen.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Xanamem® (emestedastat)
Description

Lead compound - an oral therapeutic designed to control brain cortisol levels by inhibiting the 11β-HSD1 enzyme, being developed for Alzheimer's disease, Major Depressive Disorder, and Fragile X Syndrome.

actinogen.com.au
Core offering1 text field

Actinogen Medical is developing Xanamem (emestedastat), a first-in-class, once-daily oral therapeutic that inhibits the 11β-HSD1 enzyme to control elevated cortisol production inside brain cells, targeting the hippocampus and frontal cortex. The investigational drug is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder (MDD), and Fragile X Syndrome, and is currently in Phase 2b/3 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Positive interim analysis outcome - DMC recommended trial continue without amendment
+2 more records
Product overview1 text field

Actinogen Medical is developing Xanamem (emestedastat), a first-in-class oral therapeutic that controls elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. The product is being developed as a treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The company operates across multiple clinical trials including the XanaMIA Phase 2b/3 pivotal trial in Alzheimer's disease, completed Phase 2a XanaCIDD trial in depression, and ongoing research in Fragile X Syndrome. Xanamem is an investigational drug not yet approved by any regulatory authority.

Product and service1 record
1Xanamem (emestedastat)
CategoryInvestigational Neurology Pharmaceutical
Description

Xanamem is a first-in-class, once-daily oral therapeutic designed to control elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. It is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The drug is an investigational product not yet approved by any regulatory authority and is currently being studied in the XanaMIA Phase 2b/3 pivotal Alzheimer's trial with 247 enrolled participants.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeOthers
Description

External auditors providing independent financial statement audit services. Located at 11 Mounts Bay Road, Perth WA 6000.

Strategic tierMinorTypeOthers
Description

Share registrars managing the company's share register on behalf of Actinogen. Provides shareholder services including inquiries and documentation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing small-molecule therapeutics (e.g., blarcamesine/ANAVEX 2-73) for Alzheimer's disease and other CNS indications including Rett syndrome. Directly comparable to Actinogen as a small-cap, CNS-focused, clinical-stage developer pursuing novel non-amyloid mechanisms in AD.

2Cassava Sciences
TypeDirect peer
Description

Clinical-stage biotech developing simufilam for Alzheimer's disease, a small molecule with a novel mechanism targeting altered filamin A. Closely comparable to Actinogen as a US-listed, small-cap biotech running pivotal-stage trials in AD with a differentiated non-amyloid approach.

TypeDirect peer
Description

Swiss clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases including Alzheimer's. Highly comparable to Actinogen as a clinical-stage AD-focused company advancing multiple programs through partnerships with larger pharma.

TypeDirect peer
Description

Clinical-stage CNS biotech developing novel small-molecule therapies (e.g., Zurzuvae/zuranolone for MDD/postpartum depression). Comparable to Actinogen as a small-molecule CNS specialist with depression as a lead indication and a first-in-class GABA receptor mechanism.

TypeDirect peer
Description

Clinical-stage CNS biotech developing xanomeline-trospium (Cobenfy) for schizophrenia and other CNS indications. Comparable to Actinogen as a small-molecule CNS specialist achieving pivotal-trial success and a major pharma acquisition (acquired by Bristol Myers Squibb for $14B in 2024).

TypeEmerging player
Description

Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable to Actinogen as a clinical-stage neuroscience specialist, though focused on biologics rather than small molecules.

TypeEmerging player
Description

Clinical-stage biotech developing CT1812 (zervimesine), a small-molecule sigma-2 receptor antagonist for Alzheimer's disease. Comparable to Actinogen as a small-cap clinical-stage AD biotech with a differentiated non-amyloid mechanism in pivotal trials.

8Eisai Co., Ltd.
TypeBroad incumbent
Description

Japanese pharmaceutical company and co-developer of Leqembi (lecanemab), the leading approved anti-amyloid antibody for early Alzheimer's. Highly relevant incumbent peer and likely future competitor/partner for Actinogen given Eisai's deep AD commercial infrastructure.

TypeBroad incumbent
Description

Large biotech co-developer and commercializer of Leqembi (lecanemab) for Alzheimer's and Aduhelm (aducanumab). Key incumbent establishing the AD market that Xanamem would enter; potential strategic partner or acquirer given Actinogen's CNS focus.

TypeBroad incumbent
Description

Major pharmaceutical company with Kisunla (donanemab) approved for early Alzheimer's and a deep neuroscience pipeline including depression assets. Most consequential incumbent peer that would shape commercial dynamics if Xanamem reaches market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actinogen Medical

Neurology Pharmaceuticalsactinogen.com.au

Actinogen Medical firmographics

Firmographics
Name
Actinogen Medical
Legal name
Actinogen Medical Limited
Website
https://actinogen.com.au
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Actinogen Medical industry classification

Industry
Product category
Neurology Pharmaceuticals
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical-stage biotechnology
  • Neurological therapeutics
  • Alzheimer's disease treatment
  • CNS drug development
  • Cortisol inhibition therapy

Where Actinogen Medical is headquartered

Location

Headquarters

HQ city
Sydney
HQ country
Australia
HQ region
Oceania

Offices2 records

Markets served

Actinogen Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Revenue: Pre-revenue clinical stage company. Xanamem is an investigational product not yet approved for commercial use. The company is preparing for potential future commercialization pending successful clinical trial outcomes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Actinogen Medical product offering

Product offering

Core offering

Actinogen Medical is developing Xanamem (emestedastat), a first-in-class, once-daily oral therapeutic that inhibits the 11β-HSD1 enzyme to control elevated cortisol production inside brain cells, targeting the hippocampus and frontal cortex. The investigational drug is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder (MDD), and Fragile X Syndrome, and is currently in Phase 2b/3 clinical trials.

Product overview

Actinogen Medical is developing Xanamem (emestedastat), a first-in-class oral therapeutic that controls elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. The product is being developed as a treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The company operates across multiple clinical trials including the XanaMIA Phase 2b/3 pivotal trial in Alzheimer's disease, completed Phase 2a XanaCIDD trial in depression, and ongoing research in Fragile X Syndrome. Xanamem is an investigational drug not yet approved by any regulatory authority.

Differentiator

Problem solved

Functional benefit

Brands

  • Xanamem® (emestedastat): Lead compound - an oral therapeutic designed to control brain cortisol levels by inhibiting the 11β-HSD1 enzyme, being developed for Alzheimer's disease, Major Depressive Disorder, and Fragile X Syndrome.

Products and services

  • Xanamem (emestedastat) Xanamem is a first-in-class, once-daily oral therapeutic designed to control elevated cortisol levels in the brain by inhibiting the 11β-HSD1 enzyme. It is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder, and Fragile X Syndrome. The drug is an investigational product not yet approved by any regulatory authority and is currently being studied in the XanaMIA Phase 2b/3 pivotal Alzheimer's trial with 247 enrolled participants.

Quantifiable outcome

  • Positive interim analysis outcome - DMC recommended trial continue without amendment
  • +2 more outcomes

Companies that use Actinogen Medical

Customer profile

Segments3 records

Ideal customer profiles4 records

Actinogen Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Actinogen Medical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Ernst & YoungminorOthersExternal auditors providing independent financial statement audit services. Located at 11 Mounts Bay Road, Perth WA 6000.
  • Automic Pty LtdminorOthersShare registrars managing the company's share register on behalf of Actinogen. Provides shareholder services including inquiries and documentation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Actinogen Medical competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Clinical-stage biotech developing small-molecule therapeutics (e.g., blarcamesine/ANAVEX 2-73) for Alzheimer's disease and other CNS indications including Rett syndrome. Directly comparable to Actinogen as a small-cap, CNS-focused, clinical-stage developer pursuing novel non-amyloid mechanisms in AD.
  • Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease, a small molecule with a novel mechanism targeting altered filamin A. Closely comparable to Actinogen as a US-listed, small-cap biotech running pivotal-stage trials in AD with a differentiated non-amyloid approach.
  • AC Immune: Swiss clinical-stage biotech developing therapeutics and diagnostics for neurodegenerative diseases including Alzheimer's. Highly comparable to Actinogen as a clinical-stage AD-focused company advancing multiple programs through partnerships with larger pharma.
  • Sage Therapeutics: Clinical-stage CNS biotech developing novel small-molecule therapies (e.g., Zurzuvae/zuranolone for MDD/postpartum depression). Comparable to Actinogen as a small-molecule CNS specialist with depression as a lead indication and a first-in-class GABA receptor mechanism.
  • Karuna Therapeutics: Clinical-stage CNS biotech developing xanomeline-trospium (Cobenfy) for schizophrenia and other CNS indications. Comparable to Actinogen as a small-molecule CNS specialist achieving pivotal-trial success and a major pharma acquisition (acquired by Bristol Myers Squibb for $14B in 2024).

Emerging players

  • Prothena Corporation: Clinical-stage biotech developing protein-based therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Comparable to Actinogen as a clinical-stage neuroscience specialist, though focused on biologics rather than small molecules.
  • Cognition Therapeutics: Clinical-stage biotech developing CT1812 (zervimesine), a small-molecule sigma-2 receptor antagonist for Alzheimer's disease. Comparable to Actinogen as a small-cap clinical-stage AD biotech with a differentiated non-amyloid mechanism in pivotal trials.

Broad incumbents

  • Eisai Co., Ltd. Japanese pharmaceutical company and co-developer of Leqembi (lecanemab), the leading approved anti-amyloid antibody for early Alzheimer's. Highly relevant incumbent peer and likely future competitor/partner for Actinogen given Eisai's deep AD commercial infrastructure.
  • Biogen Inc. Large biotech co-developer and commercializer of Leqembi (lecanemab) for Alzheimer's and Aduhelm (aducanumab). Key incumbent establishing the AD market that Xanamem would enter; potential strategic partner or acquirer given Actinogen's CNS focus.
  • Eli Lilly and Company: Major pharmaceutical company with Kisunla (donanemab) approved for early Alzheimer's and a deep neuroscience pipeline including depression assets. Most consequential incumbent peer that would shape commercial dynamics if Xanamem reaches market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Actinogen Medical social profiles

Digital presence

Actinogen Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actinogen Medical leadership team

Management profile

Number of profiles

Profiles12 records

Actinogen Medical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actinogen Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actinogen Medical

What does Actinogen Medical do?

Actinogen Medical is developing Xanamem (emestedastat), a first-in-class, once-daily oral therapeutic that inhibits the 11β-HSD1 enzyme to control elevated cortisol production inside brain cells, targeting the hippocampus and frontal cortex. The investigational drug is being developed as a potential treatment for Alzheimer's Disease, Major Depressive Disorder (MDD), and Fragile X Syndrome, and is currently in Phase 2b/3 clinical trials.

Is Actinogen Medical a public or private company?

Actinogen Medical is a public company. It is classified as public and is currently operating.

When was Actinogen Medical founded?

Actinogen Medical was founded in 2013. It employs 11 to 50 people.

Where is Actinogen Medical based?

Actinogen Medical is headquartered in Sydney, Australia, in the Oceania region.

How does Actinogen Medical make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Actinogen Medical's main competitors?

Direct peers on record are Anavex Life Sciences, Cassava Sciences, AC Immune, Sage Therapeutics and Karuna Therapeutics. Emerging players are Prothena Corporation and Cognition Therapeutics. Broad incumbents are Eisai Co., Ltd., Biogen Inc. and Eli Lilly and Company.

Does Actinogen Medical have an API?

No public API is recorded for Actinogen Medical.

What industry is Actinogen Medical in?

Actinogen Medical's product category is Neurology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 54171 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaActinogen Medical Limited (ATGGF) Discusses Xanamem Trial Results in Older Patients With Alzheimer's Disease TranscriptActinogen Medical reported positive trial results for Xanamem in older patients with mild to moderate Alzheimer's disease over 36 weeks. The benefit was significant in participants over 75, half the trial population, with good longer-term safety. The company sees this as a viable commercial opportunity in an unserved market segment.BioSpaceActinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%Actinogen Medical's Xanamem failed to slow Alzheimer's decline in a pivotal trial of 247 patients, with a non-significant 0.10-point benefit. The stock fell over 80% to under 1¢, but the company plans to submit findings to the FDA, citing a subgroup of patients over 75 showing a 30% slowing.TradingViewActinogen Medical Limited (ACW) Reports Significant Benefit in Participants Over 75Actinogen reported XanaMIA results from 247 patients treated for 36 weeks, showing stable disease rates of 40% versus 22% with placebo in participants over 75 (p=0.02). The overall primary endpoint difference was 0.10 CDR-SB points (p=0.65), not statistically significant. The company plans partner and FDA discussions.The AustralianActinogen Alzheimer’s drug Xanamem phase 2b/3 trial results revealedActinogen reported phase 2b/3 trial results for its Alzheimer's drug Xanamem, which slowed disease progression by 30% in patients over 75 but not in the overall group. The next trial will involve 700 patients starting mid-2027, with a 2030 market launch target.ProactiveinvestorsActinogen Medical nears key XanaMIA trial readout - ICYMIActinogen Medical completed the final patient visit in its XanaMIA Phase 2b/3 Alzheimer's trial in September, with topline results due in November. The company holds a pro-forma cash position of about A$21.9 million, and a positive result would likely trigger discussions with global pharmaceutical partners.EIN PresswireActinogen Medical enters ‘database lock’ to process XanaMIA’ data and confirm findingsActinogen Medical entered database lock for its XanaMIA Alzheimer's trial, with results due mid-November. The 36-week study of 247 patients tested Xanamem, an oral enzyme inhibitor targeting brain cortisol. CEO Dr Steven Gourlay expects positive results to establish brain cortisol control as treatable in Alzheimer's.EIN PresswireActinogen Medical closes September quarter with XanaMIA readout in sightActinogen Medical closed September with its XanaMIA Phase 2b/3 Alzheimer's trial on track for November topline results and a pro-forma cash position of about A$21.9 million. The final patient visit was completed in late September, and 87% of eligible participants moved into the open-label extension. The company expects trial-related cash burn to decline as the study concludes.ProactiveinvestorsActinogen Medical secures $4.77 million option underwriting ahead of pivotal Alzheimer’s trial resultsActinogen Medical secured $4.77 million in additional funding after Forrest Capital agreed to fully underwrite the exercise of its remaining unlisted options. The underwriting ensures the company receives the full amount even if existing option holders do not exercise before September expiry dates. Combined with existing cash, the funding extends the company's runway beyond the November 2026 XanaMIA trial readout.ProactiveinvestorsActinogen Medical to discuss future of Alzheimer’s treatment as pivotal XanaMIA readout approachesActinogen Medical Ltd is hosting a webinar to discuss the future of Alzheimer’s treatment as it approaches the pivotal XanaMIA clinical trial readout expected in November 2026. The company's lead drug candidate, Xanamem, has completed enrollment and passed safety reviews, with sufficient cash reserves to fund operations through mid-2027.YahooThe Small Cap Watch: Healthcare, critical minerals and gold explorers advance projectsProactive's Small Cap Watch covered Australian small cap companies across healthcare, critical minerals, and gold sectors providing project updates. Actinogen Medical announced it will present at the Bioshares Biotech Summit on its oral Alzheimer's treatment Xanamem, with pivotal trial results expected in November 2026 involving 247 participants. Two other companies—Askari Metals and Mount Ridley Mines—also provided corporate and operational updates, including a CFO appointment and completion of a mineralogy study at the Grass Patch rare earths project in Western Australia.